CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
EPIC IMPOCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04013737
NCT04013737N/ACompleted

Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care

Imperial College London·observational·Posted Jul 10, 2019·Updated Aug 31, 2021

In Brief

An observational study evaluating EPIC IMPOC for Antibiotic Resistant Infection and Infection. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Antimicrobials (drugs that kill or stop the growth of microorganisms including bacteria, thereby treating infections) commonly used to treat patients with infections are becoming less effective over time as bacteria develop resistance to them. Antimicrobial usage itself can lead to development and spread of antimicrobial resistance. Antimicrobial resistance is now a major threat to patient safety. To conserve the effectiveness of antimicrobials the investigator need to develop ways to use them more sensibly healthcare professionals who diagnose and treat infections must be able to access antimicrobial guidelines and test results at the patient bedside. This needs to be provided rapidly and with support to make sure that the decisions on prescribing antimicrobials are the best that can be made.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 10, 2019
Enrollment StartFeb 28, 2017
Primary CompletionAug 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.0 years ago

Interventions

EPIC IMPOCdevice

Clinical Decision Support System for antibiotic prescribing.